Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
This phase 3 randomized clinical trial assesses whether dasatinib given at 80 mg/m2 is more effective than imatinib mesylate at 300 mg/m2 to improve event-free survival in children with Philadelphia chromosome–positive acute lymphoblastic leukemia.